Arrowhead Pharmaceuticals, Inc. (ARWR)
| Previous Close | 23.13 |
| Open | 22.76 |
| Bid | 22.84 x 100 |
| Ask | 23.03 x 100 |
| Day's Range | 22.60 - 23.17 |
| 52 Week Range | 20.67 - 42.48 |
| Volume | |
| Avg. Volume | 1,277,995 |
| Market Cap | 2.841B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.77 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.38 |
Business WireArrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
PASADENA, Calif., April 29, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Business WireArrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
PASADENA, Calif., April 26, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key
Business WireArrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
PASADENA, Calif., April 24, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024.
